January 14, 2012 -- Participants were optimistic about China at last week’s J.P. Morgan Healthcare Conference, showing lots of optimism and getting real deals done; Amerigen Pharma announced two new cross-border relationships: with Shanghai Fosun Omni Pharma, Amerigen will develop controlled release oral generic drugs, and the company also signed an MOU with VIWA Pharma to develop branded generics for the China market; a Shanghai Pharma subsidiary acquired a 51% stake in Shanghai Jinhe Biotechnology; NovaBay® Pharma will use Pioneer Pharma to commercialize its wound cleaning product; Jiangsu Hengrui Medicine and Crown Bioscience will develop a novel monoclonal antibody; Aeras partnered with the China National Biotec Group to develop a recombinant TB vaccine; and Mindray Medical reported 2011 revenues rose 25% to $878 million. More details….
Stock Symbols: (SHA: 601607, HK: 2607) (AMEX: NBY) (SHA: 600276) (NYSE: MR)
